IL227770A0 - Preparations containing an opioid agonist and a separated antagonist - Google Patents

Preparations containing an opioid agonist and a separated antagonist

Info

Publication number
IL227770A0
IL227770A0 IL227770A IL22777013A IL227770A0 IL 227770 A0 IL227770 A0 IL 227770A0 IL 227770 A IL227770 A IL 227770A IL 22777013 A IL22777013 A IL 22777013A IL 227770 A0 IL227770 A0 IL 227770A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
opioid agonist
sequestered antagonist
sequestered
antagonist
Prior art date
Application number
IL227770A
Other languages
English (en)
Hebrew (he)
Original Assignee
Alpharma Pharmaceuticals Llc
Edward Scott Wilson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Pharmaceuticals Llc, Edward Scott Wilson filed Critical Alpharma Pharmaceuticals Llc
Publication of IL227770A0 publication Critical patent/IL227770A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL227770A 2011-02-02 2013-08-01 Preparations containing an opioid agonist and a separated antagonist IL227770A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161438882P 2011-02-02 2011-02-02
PCT/IB2012/050348 WO2012104752A1 (en) 2011-02-02 2012-01-25 Pharmaceutical composition comprising opioid agonist and sequestered antagonist

Publications (1)

Publication Number Publication Date
IL227770A0 true IL227770A0 (en) 2013-09-30

Family

ID=45607315

Family Applications (1)

Application Number Title Priority Date Filing Date
IL227770A IL227770A0 (en) 2011-02-02 2013-08-01 Preparations containing an opioid agonist and a separated antagonist

Country Status (14)

Country Link
US (1) US20140141090A1 (OSRAM)
EP (1) EP2670400A1 (OSRAM)
JP (3) JP2014504630A (OSRAM)
KR (4) KR20180027641A (OSRAM)
CN (1) CN103415285A (OSRAM)
AU (3) AU2012213056A1 (OSRAM)
BR (1) BR112013019431A2 (OSRAM)
CA (1) CA2824835A1 (OSRAM)
IL (1) IL227770A0 (OSRAM)
MX (1) MX2013008225A (OSRAM)
RU (1) RU2013136350A (OSRAM)
SG (1) SG191872A1 (OSRAM)
WO (1) WO2012104752A1 (OSRAM)
ZA (1) ZA201305108B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058447A1 (en) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
BR112012024019B1 (pt) 2010-03-24 2021-10-19 Jazz Phamaceuticals, Inc Forma de dosagem de liberação controlada para administração oral
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US11690840B2 (en) * 2017-10-09 2023-07-04 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
MX2021005691A (es) 2018-11-19 2021-07-07 Jazz Pharmaceuticals Ireland Ltd Formulaciones de farmacos resistentes al alcohol.
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
KR20230071228A (ko) 2021-11-16 2023-05-23 김명진 가상공간에 사용자가 마시는 주류를 적용하기 위한 방법 및 장치
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
WO2001058447A1 (en) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
CN2423892Y (zh) * 2000-04-30 2001-03-21 尹为民 分隔式药物胶囊
CA2778114A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
ES2326794T3 (es) * 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
AU2005240137B2 (en) 2004-05-04 2010-04-15 Innophos, Inc. Directly compressible tricalcium phosphate
PT2484346T (pt) 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
CN101461809A (zh) * 2007-12-18 2009-06-24 重庆药友制药有限责任公司 一种泮托拉唑钠肠溶片及其制备方法
WO2012056402A2 (en) * 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose

Also Published As

Publication number Publication date
JP2014504630A (ja) 2014-02-24
CN103415285A (zh) 2013-11-27
KR20160031038A (ko) 2016-03-21
AU2017204639A1 (en) 2017-07-27
US20140141090A1 (en) 2014-05-22
EP2670400A1 (en) 2013-12-11
JP2018109059A (ja) 2018-07-12
JP2017081942A (ja) 2017-05-18
ZA201305108B (en) 2014-09-25
AU2012213056A1 (en) 2013-07-25
MX2013008225A (es) 2013-08-12
CA2824835A1 (en) 2012-08-09
KR20180027641A (ko) 2018-03-14
KR20130124551A (ko) 2013-11-14
RU2013136350A (ru) 2015-03-27
SG191872A1 (en) 2013-08-30
WO2012104752A1 (en) 2012-08-09
KR20190014577A (ko) 2019-02-12
AU2016200708A1 (en) 2016-02-25
BR112013019431A2 (pt) 2020-10-27

Similar Documents

Publication Publication Date Title
IL227770A0 (en) Preparations containing an opioid agonist and a separated antagonist
IL230819A0 (en) Refractory oral pharmaceutical dosage form containing an opioid agonist and an opioid antagonist
IL228506A (en) Opioid receptor ligands and pharmacy preparations containing them
PL2549984T3 (pl) Formulacje farmaceutyczne o podwójnej warstwie zawierające agonistów i antagonistów opioidów
IL230010B (en) Inhalable pharmaceutical ingredients
IL226382B (en) Integrin agonist compounds and medicinal compositions thereof.
IL229409A0 (en) Intravenous pharmaceutical dosage forms containing naloxone
IL230859A0 (en) Compounds and methods for monitoring allelic variants
HUE036253T2 (hu) E-szelektin antagonista vegyületek
EP2683243A4 (en) PI3 KINASE INHIBITORS AND USES THEREOF
IL230861A (en) A rapidly dissolving pharmaceutical composition
ZA201400501B (en) New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
IL222087A (en) A fast-dissolving pharmaceutical preparation
IL222086A (en) A pharmaceutical composition that melts quickly
IL215813A0 (en) Pariticulate pharmaceutical composition with an opioid and an opioid antagonist
GB2525835B (en) Pharmaceutical agent
SMT201500005B (it) Composizione framaceutica inalabile
EP2675276A4 (en) PERIPHERAL MY OPIOID ANTAGONISTS
IL229417A0 (en) A pharmaceutical preparation containing fexofenadine
PT2802311T (pt) Composição farmacêutica sublingual contendo um agente anti-histamínico e método para a sua preparação
EP2776064A4 (en) ANTAGONISTS OF PRO-VASOPRESSIN AND USES THEREOF
PT2744781T (pt) Derivados de fentanilo como agonistas de receptores de opióides dependentes do ph
PL2709599T3 (pl) Kompozycja farmaceutyczna zawierająca drotawerynę
GB201301179D0 (en) Pharmaceutical composition comprising opioid analgesic
HK1197536A (en) Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent